MedTrace Logo

EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors

NCT06541639 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2025-03-18

No results posted yet for this study

Summary

The goal of this clinical trial is to learn the side effects, safety and effect of a tumor vaccine (EVM16) alone or in combined with an anti-PD-1 antibody (tislelizumab) . This clinical trial will include solid tumor patients who failed standard treatment.

The main questions to answer are:

Safety of EVM16. Suitable dose of EVM16. Effects of EVM16 combined with tislelizumab.

Conditions

  • Advanced or Recurrent Solid Tumors

Interventions

BIOLOGICAL

EVM16

cancer vaccine

DRUG

Tislelizumab

Anti-PD1 antibody

Sponsors & Collaborators

  • Shanghai Cancer Centre

    collaborator OTHER

  • Everest Medicines (China) Co.,Ltd.

    collaborator INDUSTRY

  • Peking University

    lead OTHER

Principal Investigators

  • Lin Shen, MD · Peking University Cancer Hospital & Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-04
Primary Completion
2028-03-31
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06541639 on ClinicalTrials.gov